contezolid

Contezolid is a novel, orally active oxazolidinone antibiotic developed for the treatment of complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), Streptococcus pyogenes, and Streptococcus agalactiae[1][2][5]. It was rationally designed to address the myelosuppression and monoamine oxidase inhibition limitations associated with linezolid[2]. Contezolid acts by inhibiting bacterial protein synthesis through binding to the V region of bacterial 23S rRNA in the 50S ribosomal subunit, thereby preventing formation of a functional 70S initiation complex essential for translation[2][5][8]. Compared to linezolid, contezolid demonstrates similar or improved antibacterial efficacy with reduced hematologic toxicity such as myelosuppression[3][6]. It was approved in China in June 2021 for cSSTI treatment[2][3].

Brand names

Youxitai

Other names

contezolid